Clinical Trial

Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

Name: Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma — clinical trial record (NCT06871007)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 1/2

View on ClinicalTrials.gov →

Summary

Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma

Trial Details

NCT Number	NCT06871007
Lead Sponsor	St. Petersburg State Pavlov Medical University
Conditions	Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab
Enrollment	22 participants
Start Date	2024-09-01
Primary Completion	2029-09-01 (estimated)
Study Completion	2031-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-11